JP2018508526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508526A5 JP2018508526A5 JP2017546181A JP2017546181A JP2018508526A5 JP 2018508526 A5 JP2018508526 A5 JP 2018508526A5 JP 2017546181 A JP2017546181 A JP 2017546181A JP 2017546181 A JP2017546181 A JP 2017546181A JP 2018508526 A5 JP2018508526 A5 JP 2018508526A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- therapeutic agent
- subject
- psc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129698P | 2015-03-06 | 2015-03-06 | |
| US62/129,698 | 2015-03-06 | ||
| PCT/US2016/020819 WO2016144720A1 (en) | 2015-03-06 | 2016-03-04 | Method of treating primary sclerosing cholangitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508526A JP2018508526A (ja) | 2018-03-29 |
| JP2018508526A5 true JP2018508526A5 (https=) | 2019-04-11 |
| JP6942053B2 JP6942053B2 (ja) | 2021-09-29 |
Family
ID=55699788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546181A Active JP6942053B2 (ja) | 2015-03-06 | 2016-03-04 | 原発性硬化性胆管炎を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180051086A1 (https=) |
| EP (2) | EP3265492A1 (https=) |
| JP (1) | JP6942053B2 (https=) |
| KR (1) | KR20170120622A (https=) |
| AU (1) | AU2016229193A1 (https=) |
| BR (1) | BR112017019071A2 (https=) |
| CA (1) | CA2978725A1 (https=) |
| EA (1) | EA201791970A1 (https=) |
| MA (1) | MA41636A (https=) |
| MX (1) | MX2017011272A (https=) |
| WO (1) | WO2016144720A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| AU2017234010B2 (en) * | 2016-03-14 | 2024-06-13 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| CA3017743A1 (en) * | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| EP3468597A1 (en) | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| JP7778567B2 (ja) * | 2019-04-17 | 2025-12-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | α４β７阻害薬及びＩＬ－２３阻害薬の併用療法 |
| CN114375307B (zh) * | 2019-06-10 | 2025-12-05 | 武田药品工业株式会社 | 产生抗α4β7抗体的方法 |
| JP7411875B2 (ja) | 2020-10-08 | 2024-01-12 | 株式会社 キュロム・バイオサイエンス | ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| WO1999058573A1 (en) * | 1998-05-13 | 1999-11-18 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
| NZ566263A (en) | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| KR100874292B1 (ko) | 2002-11-18 | 2008-12-18 | 케모센트릭스 | 아릴 술폰아마이드 |
| WO2006026759A2 (en) | 2004-09-03 | 2006-03-09 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| EP1948691A1 (en) * | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2016
- 2016-03-03 MA MA041636A patent/MA41636A/fr unknown
- 2016-03-04 EA EA201791970A patent/EA201791970A1/ru unknown
- 2016-03-04 BR BR112017019071A patent/BR112017019071A2/pt not_active Application Discontinuation
- 2016-03-04 AU AU2016229193A patent/AU2016229193A1/en not_active Abandoned
- 2016-03-04 CA CA2978725A patent/CA2978725A1/en not_active Abandoned
- 2016-03-04 EP EP16715375.8A patent/EP3265492A1/en not_active Withdrawn
- 2016-03-04 WO PCT/US2016/020819 patent/WO2016144720A1/en not_active Ceased
- 2016-03-04 US US15/556,186 patent/US20180051086A1/en not_active Abandoned
- 2016-03-04 MX MX2017011272A patent/MX2017011272A/es unknown
- 2016-03-04 KR KR1020177025412A patent/KR20170120622A/ko not_active Withdrawn
- 2016-03-04 EP EP22213419.9A patent/EP4257200A3/en active Pending
- 2016-03-04 JP JP2017546181A patent/JP6942053B2/ja active Active
-
2021
- 2021-02-24 US US17/184,116 patent/US12391760B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508526A5 (https=) | ||
| JP7579227B2 (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2021502961A5 (https=) | ||
| EP3983439A1 (en) | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer | |
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2017537105A5 (https=) | ||
| JP2016515120A5 (https=) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| JP2017503820A5 (https=) | ||
| JP2017522307A5 (https=) | ||
| RU2017120437A (ru) | Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r | |
| JP2017507139A5 (https=) | ||
| Terashima et al. | Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma | |
| JP2016522164A5 (https=) | ||
| JP2019514974A5 (https=) | ||
| JP2024038034A5 (https=) | ||
| Yoo et al. | Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization | |
| Gleason et al. | Atezolizumab-induced psoriasiform drug eruption successfully treated with ixekizumab: a case report and literature review | |
| AU2021269832B2 (en) | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| JP6351828B2 (ja) | 肝細胞癌の抗ｖｅｇｆｒ２抗体治療 | |
| TW202527995A (zh) | 抗b7h3抗體藥物偶聯物在製備治療鼻咽癌和/或肺淋巴上皮瘤樣癌的藥物中的用途 | |
| JP2022125157A (ja) | 抗－ｖｅｇｆｒ－２抗体 | |
| KR20190120339A (ko) | 수술적 절제 후 간세포암종 환자를 치료하기 위한 약제의 제조에서 황산화된 올리고당류의 용도 | |
| Delis et al. | Sclerosing cholangitis in the era of target chemotherapy: a possible anti-VEGF effect |